Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study

Tehlirian, C; Singh, RSP; Pradhan, V; Roberts, ES; Tarabar, S; Peeva, E; Vincent, MS; Gale, JD

Gale, JD (通讯作者)，Pfizer Inc, Inflammat & Immunol Res, 1 Portland St, Cambridge, MA 02139 USA.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022; 87 (2): 333

Abstract

Background: Psoriasis treatments lack durable efficacy and have inconvenient administration, highlighting the need for new therapies. Objective: To ev......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索